Neoadjuvant pembrolizumab plus gemcitabine with or without cisplatin led to high rates of downstaging to non–muscle invasive urothelial cancer in patients with muscle-invasive urothelial cancer, meeting the primary end points for both cohorts of the phase 1b/2 HCRN GU14-188 trial.
StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research note released on Thursday. The firm issued a hold rating on the stock. JNCE has been the topic of a number of other research reports. Raymond James downgraded shares of Jounce Therapeutics from an outperform rating to a market perform […]
Investment analysts at StockNews.com began coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the stock. JNCE has been the topic of a number of other reports. Piper Sandler lowered shares of Jounce Therapeutics from an […]
Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) has earned an average rating of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among analysts […]